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Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious 
vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure 
process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing 
severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the 
global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks 
to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of 
serious disease following natural infection, if they have a high baseline risk of natural infection, and if during the trial they receive 
frequent monitoring and, following any infection, the best available care.
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Alleviation of the enormous burden of mortality and morbidity 
associated with the COVID-19 pandemic will probably depend 
on the development of effective vaccines that could be rolled 
out widely. Many candidate vaccines are in development [1], but 
recent estimates cite at least 1–1.5 years to vaccine rollout [2]. 
A significant proportion of that time is due to the requirement 
to assess efficacy and safety in placebo-controlled phase 3 trials, 
which typically involve several thousand participants followed 
for long enough in the field to assess differences in disease inci-
dence between vaccine and control groups, with many partici-
pants taking precautions to avoid exposure. We suggest that, in 
the circumstances of a devastating global pandemic, controlled 
human challenge studies (following the normal initial safety, 
vaccine dose finding, and immunogenicity studies—phases 1/2 
in Figure 1) may be an acceptable way to bypass phase 3 testing, 
and speed the licensure of efficacious vaccines.
THE PROPOSED STUDY DESIGN
Volunteers for human challenge studies would be drawn from 
previously uninfected individuals at relatively low risk of 
complications or mortality from SARS-CoV-2 infection (eg, 
young adults, without chronic health conditions, and not oth-
erwise sick) [3–7] and who are at substantial risk of natural 
exposure to SARS-CoV-2 (eg, resident in areas with high trans-
mission rates). Such a target group might comprise uninfected 
persons aged 20–45  years, an age range in which the risk of 
death or serious complications following infection is substan-
tially lower than in older age groups [4, 5].
The controlled challenge model would need to be stand-
ardized before using it to test vaccines. Volunteers, previously 
uninfected, would be required for an initial dose-escalation 
study of the viral challenge to select a dose of virus exposure 
such that most placebo recipients become infected (for statis-
tical reasons), and have a clinical response that is not more se-
vere than the one associated with natural infection (for ethical 
reasons). The latter would require comparison with a cohort of 
individuals of similar age who had been infected naturally. For 
this standardization, volunteers may spend 2 weeks in a clinical 
isolation facility prior to the challenge, with viral and serologic 
testing, to exclude those with previous or recent infection (or a 
shorter duration if suitable serological tests for recent infections 
are developed). Overall, these preparatory studies (upper-left 
black square in Figure 1) may take several weeks and could start 
before vaccine candidates are available for evaluation.
Multiple measures would be put in place to ensure that, prior 
to consenting, potential participants fully comprehend the unu-
sual risks involved in the study.
After the controlled human challenge model had been set 
up, vaccines could be evaluated. Volunteers who had not been 
previously infected would be randomized to receive either the 
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candidate vaccine(s) under investigation or placebo. After an 
interval to permit a full immune response to the vaccine, a 
controlled exposure to SARS-CoV-2 would be administered. 
Appropriate vaccine schedules (eg, dose, number of doses) will 
have been determined, to the extent possible, in the conven-
tional phase 1/2 immunogenicity and safety studies that pre-
ceded the challenge study.
Following the challenge, the participants would be carefully 
followed, to monitor whether those vaccinated had a different 
response to viral challenge. Because the challenge studies would 
be relatively small and some volunteers might show few clinical 
symptoms, there would need to be careful consideration of the 
choice of the primary endpoint, through discussions with regu-
latory authorities. Possibilities would include viral load, meas-
ured at least daily (eg, in throat swabs), and then cumulated 
over the course of the infection (as has been done in influenza 
challenge studies) [8], and time to first clinical symptoms. For 
some vaccines, the endpoint might be the proportion infected. 
Throughout the study, intense immunological monitoring 
would seek any correlates of vaccine effect. The required size 
of such studies would depend upon the endpoints chosen, but 
they might require of the order of 100 volunteers.
Any volunteers in whom infection was confirmed would 
receive excellent care for COVID-19, including priority for 
any scarce life-saving resources, in state-of-the-art facilities. 
Throughout the trial and until infectiousness was ruled out, all 
participants would remain isolated in a secure and comfortable 
setting (eg, in settings converted from those used for influenza 
challenge studies).
If this human challenge study showed a vaccine candidate to 
be efficacious, an expanded placebo-controlled study would be 
conducted in the field, involving at least 3000 vaccinated per-
sons, primarily for short-term safety assessment, but also to 
gather further evidence on immunogenicity (Figure  1, right-
most black box). Participants would be carefully monitored for 
adverse effects following vaccination, to gather safety data suf-
ficient for submission for licensure. This study (not involving a 
challenge) should be conducted on the eventual primary initial 
target group for an effective vaccine—including the elderly and 
those with concomitant illnesses that increase the risk of serious 
disease following infection. With prior planning, this large-scale 
assessment of safety could be completed in several months, as 
initially only short-term adverse effects would be assessed.
Together, the information from the challenge study and the 
short-term follow-up of those in the expanded (phase 2) field 
study may produce evidence sufficient to justify accelerated 
licensure.
Participants of the expanded field study could continue to be 
followed longer term in parallel with the submission for licen-
sure, so that suitable actions could be taken if any long-term 
adverse effects, including disease enhancement, were identified. 
As with standard vaccine licensure, additional, postapproval 
studies would be required to assess safety and effectiveness 
in routine use. Any necessary studies of dosage and safety in 
special groups (eg, children, pregnant women, and immuno-
compromised persons) could be conducted, before extending 
vaccination to these groups, as judged appropriate.
It is possible that the protection that was apparent in a chal-
lenge study will not be replicated when the vaccine is used 
to protect against natural infection. This would have to be 
carefully monitored in the early stages of vaccine rollout, for 
example through case-control studies. In such an event, appro-
priate modification will be made to the vaccination program 
(including potentially stopping vaccination).
A particular concern with respect to some vaccine constructs 
against coronavirus is that they may induce more severe dis-
ease following infection, as has been reported in animal models 
of both SARS and MERS vaccine candidates [9]. If any vaccine 
candidate shows evidence of such effects in animal models, it is 
likely to be ruled out for human testing. However, for those can-
didates that are taken forward for human testing, the possibility 
of enhancement should be borne in mind and the challenge 
studies should be designed in such a way that small groups 
of volunteers are challenged sequentially. In this way, studies 
could be stopped at an early stage, upon first strong indication 
of vaccine-induced enhanced disease. If the vaccine candidate 
did enhance disease, the controlled human challenge model 
would provide much more rapid evidence to support stopping 
the testing of a harmful vaccine candidate, with far fewer vac-
cinated persons, than a traditional phase 3 efficacy study.
ACCELERATION OF LICENSURE AND SUBSTANTIAL 
SOCIAL VALUE
The proposed trial method would potentially cut the wait time 
for the rollout of an efficacious vaccine. Challenge studies 
(which always directly expose all participants to a pathogen 
to assess efficacy) generally require fewer participants, fol-
lowed over a shorter period than do standard efficacy studies 
(in which many participants are never exposed). Rollout of 
an efficacious vaccine to age groups not included in the chal-
lenge studies may depend on immunological bridging, but this 
would be a component of the expanded safety studies discussed 
above. It is possible that this process could take several months 
shorter than reliance on standard phase 3 testing to assess effi-
cacy. While rollout to other populations might require initial 
bridging studies, these could be conducted relatively quickly.
It seems clear that, in the absence of an efficacious vaccine, 
the global death toll from COVID-19 will be enormous. A re-
cent modelling study suggests that, even with mitigation strat-
egies focusing on shielding the elderly and slowing but not 
interrupting transmission, there may be 20 million this year 
[10]. If the use of human challenge helped to make the vaccine 
available before the epidemic has completely passed, the sav-
ings in human lives could be in the thousands or conceivably 
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millions. Intense social distancing and related control meas-
ures, held in place for many months between now and the 
availability of vaccine, will themselves take a toll on econ-
omies, societies, and population health. Advancing the reg-
istration and rollout of an efficacious vaccine, even by a few 
months, could save many thousands of lives, and commands 
enormous societal value.
AUTONOMOUS AUTHORIZATION
Deliberate exposure of study participants to SARS-CoV-2 gives 
rise to understandable ethical worries. It may seem impermis-
sible to ask people to take on risk of severe illness or death, even 
for an important collective gain. But we actually ask people to 
take such risks for others’ direct gain every time we ask vol-
unteer firefighters to rush into burning buildings, relatives to 
donate a live organ to loved ones, healthy volunteers to par-
ticipate in drug and vaccine toxicity trials with no prospect of 
improving their health (and some risk of undermining it) [11], 
relatively healthy volunteers to participate in studies involving 
long antiretroviral drug interruptions that risk their health with 
negligible prospect of improving it [12], and other challenge 
studies in which healthy volunteers expose themselves to patho-
gens [13]. This spring, we are clearly within our right when we 
invite citizens to volunteer for Emergency Medical Services 
(EMS) to fight a pandemic that augments both the personal 
risks for EMS workers and the social value of their work, and 
initial trials for the Moderna SARS-CoV-2 vaccine are being 
accelerated by skipping prior animal testing and the margin of 
safety that it would have added [14].
One major reason why it is permissible to risk medical harm 
to volunteers in medical studies, even when their personal 
health care does not require that risk, is that these volunteers 
will have autonomously consented to take on these risks. Adult 
persons can legitimize many interventions in their bodies and 
health that are normally prohibited, simply by saying “Yes,” with 
full understanding and voluntariness. In the present case, the 
study would involve multiple tests of comprehension of all risks 
(and the risk factors for serious outcomes among individuals in 
otherwise low-risk age groups may be somewhat clearer by the 
time recruitment takes place), so that the decision is deeply in-
formed and voluntary. The exclusive recruitment of participants 
aged 20–45 years, although children are less likely to have severe 
symptoms upon COVID-19 infection [6, 7], seeks to safeguard 
the quality of participants’ consent. The wide news coverage and 
widespread fear of Covid-19 should keep it clear that exposure 
to this virus is no small matter. While in other studies men-
tioned above, nonconsenting sex partners and fetuses of study 
participants may get infected [15, 16], the proposed controlled 
challenge study would avoid risk to nonparticipants by isolating 
participants whilst infectious.
ADDED RISK REMAINS ACCEPTABLE
But a remaining key question, for deeming human challenge 
studies ethical, pertains to risk. Are the risks to partici-
pants, even when they are justified by the social importance 
of the trial and backed by participants’ willful permission, 
also being kept to the necessary minimum? And do the risks 
fall below a postulated cap on the acceptable risk of medical 
trials, even ones of the highest social value and with partici-
pants’ consent [15]?
The proposed challenge studies seek to contain the risk to 
participants in 6 different ways. First, the study will recruit only 
healthy patients from age groups in which the risk of severe dis-
ease and death following SARS-CoV-2 infection is low. Second, 
there is the possibility that the vaccine candidate will protect at 
least some of those who are vaccinated. Third, in the absence of 
an effective vaccine, a high proportion of the general popula-
tion is likely to be naturally infected with SARS-CoV-2 at some 
point [17], including those who might participate in a challenge 
study; by volunteering to be artificially infected they may be just 
hastening an event that is likely to occur in later months an-
yhow. Fourth, only people with an especially high baseline risk 
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Figure 1. The process to vaccine licensure through a controlled human challenge trial and large study to assess short-term safety (black) compared to the conventional 
phase 3 trial route to licensure (grey). Submission for licensure could occur substantially earlier with a controlled human challenge trial.
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of getting exposed during or soon after the trial period should 
be recruited (eg, people residing in areas with high transmission 
rates). Fifth, participants would be monitored carefully and fre-
quently following the challenge and afforded the best available 
care if needed (eg, guaranteed access to state-of-the-art facilities 
of the health system, notwithstanding the possibility of severe 
shortages of medical care during the evolving pandemic). Sixth, 
by the time vaccine candidates are being tested, some thera-
peutics may be approved, which may reduce participants’ risk 
of morbidity and mortality further. For these 6 reasons, mor-
tality and morbidity from participation notwithstanding, net 
mortality and morbidity from participation should remain low 
or negative.
CONCLUSION
A novel strain of coronavirus forces us to consider unconven-
tional approaches. We believe that controlled SARS-CoV-2 
vaccine challenge studies may accelerate the time it takes to 
evaluate and license vaccines and hence could make vaccines 
available sooner for widespread rollout. Such an approach is 
not without risks, but every week that vaccine rollout is de-
layed will be accompanied by many thousands of deaths glob-
ally. Importantly, challenge studies are conducted against the 
background of competent volunteers’ informed consent, min-
imization of study risks, and high baseline risks of infection for 
participants. They do not violate participants’ individual rights 
on the altar of emergency response, but heed both individual 
rights and the global public health emergency.
As far as we are aware, the current plan for evaluating the 
efficacy of COVID-19 vaccines is through slower phase 3 trials. 
It will take some time to develop and operationalize challenge 
studies and we are not suggesting that ongoing development 
of any vaccines which become ready for phase 3 trials must be 
paused during this period. However, we believe that challenge 
studies could be set up before the time that most vaccines would 
be ready for efficacy testing.
In addition to their use for assessing the efficacy of vaccines, 
human challenge studies may also help evaluate drugs that might 
be given either as preexposure prophylaxis to prevent infection 
in individuals at high risk of infection, or as postexposure pro-
phylaxis, given shortly after a potential exposure, either to abort 
infection or to prevent the occurrence of disease. Challenge 
studies may also be a way of advancing understanding of the 
pathogenesis of the progression from infection to disease.
To further assess the potential of human challenge studies 
to speed vaccine development, we suggest that an expert group 
might be convened, including those with experience of human 
challenge studies of other pathogens, regulators, vaccine trial-
ists, ethicists, potential participants, and relevant funding agen-
cies, to plan if and how such studies might be taken forward 
ethically and expeditiously.
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